[Effects of low dose pimobendan in patients with cor-pulmonale].
The acute and chronic efficacy of low dose pimobendan (1.25 mg x 2/day) was evluated in patients with cor-pulmonale. Fifteen patients (12 men, 3 women, mean age 73 +/- 5 yr) with right ventricular dysfunction judged by Tei's Doppler index (> or = 0.4) and poor working capacity (exercise tolerance: 2.2-6.6 MET) were studied. Mean pulmonary artery pressure, cardiac output, total pulmonary resistance using Swan-Ganz catheter, and arterial oxygen and carbon dioxide pressure (PaO2, PaCO2) were measured before and 24 hr after pimobendan administration. Maximal oxygen intake (MET), saturation of arterial blood oxygen at rest and desaturation by treadmill stress test were measured before and 1 month after pimobendan administration. Pulmonary artery pressure decreased (17.6 +/- 4.7 to 10.2 +/- 2.3 mmHg, p < 0.001) and cardiac output increased (3.5 +/- 0.6 to 5.1 +/- 0.9 l/min, p < 0.001), resulting in decreased total pulmonary resistance (5.0 +/- 1.3 to 2.1 +/- 0.7 U, p < 0.001), and a mild decrease in PaO2 (74 +/- 8 to 70 +/- 10 mmHg, p < 0.05). Exercise tolerance improved significantly (4.8 +/- 1.7 to 6.8 +/- 2.2 MET, p < 0.001), without deterioration of PaO2 and desaturation. These results indicate that low dose pimobendan is useful for the treatment of patients with cor-pulmonale.
Nakatani
M
M
Department of Internal Medicine, Kasai Municipal Hospital, Hyogo.
Shirotani
T
T
Kobayashi
K
K
Satomi
S
S
Ikeda
Y
Y
Kuniyoshi
T
T
Tajiri
E
E
Furuta
Y
Y
Motooka
T
T
D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D010101:Oxygen Consumption; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000503:physiopathology; D011724:Pyridazines / Q000008:administration & dosage*
D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan